Affidea applies ground-breaking AI technology on Brain MRI examinations for people with Multiple Sclerosis
Affidea has entered into a partnership with icometrix, a data science company that develops Artificial Intelligence (AI) solutions for healthcare, to standardise and improve the care of patients with neurological disorders. The official announcement of the partnership has been made at ECR 2019 on the application of a ground-breaking AI tool on Brain MRI examinations for people with Multiple Sclerosis (MS).
As the leading European provider of advanced diagnostic imaging services, we are well-positioned to transform healthcare and the way we diagnose, monitor and treat people with multiple sclerosis, benefitting from a pan-European network of medical centres, reputed medical professionals and a committed ownership. Our own investor, the Waypoint Capital Group, which manages the funds of the Bertarelli family, has a deep heritage in the healthcare sector and a focus on innovative, forward-looking industries. It also owns the new digital tech fund, Forestay Capital, which recently announced an investment in icometrix to support its ambitions for growth and to transform patient care through imaging AI.
Studies have demonstrated that up to 26% of people with MS have suboptimal response to treatment and due to the complexity of the disease progression assessment it can take up to 4 years to identify the optimal therapy1. Delaying any disease modifying treatment, even for a few years, can lead to a decrease in treatment efficacy that cannot be easily regained by opting for more aggressive treatments at a later age2 . This can result in higher rates of disability for patients with MS and to higher costs for payors, be they private or public.
The new Affidea clinical product, neuroInsight|MS, ensures accurate and standardised measurements to monitor Multiple Sclerosis, resulting in an earlier prediction of disability, disease progression and treatment response. Affidea neuroInsight|MS has been implemented in clinical routine and is available in four Affidea countries – Italy, Portugal, Switzerland and Serbia.
Affidea neuroInsight|MS utilises the FDA cleared and CE approved AI software, “icobrain ms”, that is used by radiologists to enhance the reporting of Brain MRI examinations for people with MS. The enhanced report provides unique and quantifiable information about the patient’s evolution of white matter abnormalities and brain volume changes, including population graphs and statistics that can be used to objectively track the disease progression and identify the optimal bespoke treatment for each patient with MS.
Another key component of Affidea’s neuroInsight|MS is the "icompanion" application. This application is a patient reported outcome measurement (PROM) tool as well as an educational tool on the use of MRI in MS that patients can access via their smart device or through the web. People with MS are able to track symptoms in real time, and this information is then available to their treating physician between visits.
NeuroInsight|MS brings benefits to all stakeholders, and most importantly, to both doctors and people with MS.
Benefits to Doctors:
Benefits to Patients: